Cargando…
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
BACKGROUND: Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. MATERIALS AND METHODS: A descriptive analysis on 2 AE cost comparisons was conducted using patient-level data for the nivolumab-based the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847521/ https://www.ncbi.nlm.nih.gov/pubmed/36124890 http://dx.doi.org/10.1093/oncolo/oyac186 |
_version_ | 1784871469455507456 |
---|---|
author | McGregor, Bradley Geynisman, Daniel M Burotto, Mauricio Porta, Camillo Suarez, Cristina Bourlon, Maria T Del Tejo, Viviana Du, Ella X Yang, Xiaoran Sendhil, Selvam R Betts, Keith A Huo, Stephen |
author_facet | McGregor, Bradley Geynisman, Daniel M Burotto, Mauricio Porta, Camillo Suarez, Cristina Bourlon, Maria T Del Tejo, Viviana Du, Ella X Yang, Xiaoran Sendhil, Selvam R Betts, Keith A Huo, Stephen |
author_sort | McGregor, Bradley |
collection | PubMed |
description | BACKGROUND: Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. MATERIALS AND METHODS: A descriptive analysis on 2 AE cost comparisons was conducted using patient-level data for the nivolumab-based therapies and published data for the pembrolizumab-based therapies. First, grade 3/4 AE costs were compared between nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + axitinib using data from the CheckMate 214 (median follow-up [mFU]: 13.1 months), CheckMate 9ER (mFU: 12.8 months), and KEYNOTE-426 (mFU: 12.8 months) trials, respectively. Second, grade 3/4 AE costs were compared between nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + lenvatinib using data from the CheckMate 214 (mFU: 26.7 months), CheckMate 9ER (mFU: 23.5 months), and KEYNOTE-581 (mFU: 26.6 months) trials, respectively. Per-patient costs for all-cause and treatment-related grade 3/4 AEs with corresponding any-grade AE rates ≥ 20% were calculated based on the Healthcare Cost and Utilization Project database and inflated to 2020 US dollars. RESULTS: Per-patient all-cause grade 3/4 AE costs for nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + axitinib were $2703 vs. $4508 vs. $5772, and treatment-related grade 3/4 AE costs were $741 vs. $2722 vs. $4440 over ~12.8 months of FU. For nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + lenvatinib, per-patient all-cause grade 3/4 AE costs were $3120 vs. $5800 vs. $9285, while treatment-related grade 3/4 AE costs were $863 vs. $3162 vs. $5030 over ~26.6 months of FU. CONCLUSION: Patients with aRCC treated with first-line nivolumab-based therapies had lower grade 3/4 all-cause and treatment-related AE costs than pembrolizumab-based therapies, suggesting a more favorable cost-benefit profile. |
format | Online Article Text |
id | pubmed-9847521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98475212023-01-20 Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma McGregor, Bradley Geynisman, Daniel M Burotto, Mauricio Porta, Camillo Suarez, Cristina Bourlon, Maria T Del Tejo, Viviana Du, Ella X Yang, Xiaoran Sendhil, Selvam R Betts, Keith A Huo, Stephen Oncologist Genitourinary Cancer BACKGROUND: Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. MATERIALS AND METHODS: A descriptive analysis on 2 AE cost comparisons was conducted using patient-level data for the nivolumab-based therapies and published data for the pembrolizumab-based therapies. First, grade 3/4 AE costs were compared between nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + axitinib using data from the CheckMate 214 (median follow-up [mFU]: 13.1 months), CheckMate 9ER (mFU: 12.8 months), and KEYNOTE-426 (mFU: 12.8 months) trials, respectively. Second, grade 3/4 AE costs were compared between nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + lenvatinib using data from the CheckMate 214 (mFU: 26.7 months), CheckMate 9ER (mFU: 23.5 months), and KEYNOTE-581 (mFU: 26.6 months) trials, respectively. Per-patient costs for all-cause and treatment-related grade 3/4 AEs with corresponding any-grade AE rates ≥ 20% were calculated based on the Healthcare Cost and Utilization Project database and inflated to 2020 US dollars. RESULTS: Per-patient all-cause grade 3/4 AE costs for nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + axitinib were $2703 vs. $4508 vs. $5772, and treatment-related grade 3/4 AE costs were $741 vs. $2722 vs. $4440 over ~12.8 months of FU. For nivolumab + ipilimumab vs. nivolumab + cabozantinib vs. pembrolizumab + lenvatinib, per-patient all-cause grade 3/4 AE costs were $3120 vs. $5800 vs. $9285, while treatment-related grade 3/4 AE costs were $863 vs. $3162 vs. $5030 over ~26.6 months of FU. CONCLUSION: Patients with aRCC treated with first-line nivolumab-based therapies had lower grade 3/4 all-cause and treatment-related AE costs than pembrolizumab-based therapies, suggesting a more favorable cost-benefit profile. Oxford University Press 2023-01-18 /pmc/articles/PMC9847521/ /pubmed/36124890 http://dx.doi.org/10.1093/oncolo/oyac186 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Genitourinary Cancer McGregor, Bradley Geynisman, Daniel M Burotto, Mauricio Porta, Camillo Suarez, Cristina Bourlon, Maria T Del Tejo, Viviana Du, Ella X Yang, Xiaoran Sendhil, Selvam R Betts, Keith A Huo, Stephen Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma |
title | Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma |
title_full | Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma |
title_fullStr | Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma |
title_full_unstemmed | Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma |
title_short | Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma |
title_sort | grade 3/4 adverse event costs of immuno-oncology combination therapies for previously untreated advanced renal cell carcinoma |
topic | Genitourinary Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847521/ https://www.ncbi.nlm.nih.gov/pubmed/36124890 http://dx.doi.org/10.1093/oncolo/oyac186 |
work_keys_str_mv | AT mcgregorbradley grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT geynismandanielm grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT burottomauricio grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT portacamillo grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT suarezcristina grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT bourlonmariat grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT deltejoviviana grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT duellax grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT yangxiaoran grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT sendhilselvamr grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT bettskeitha grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma AT huostephen grade34adverseeventcostsofimmunooncologycombinationtherapiesforpreviouslyuntreatedadvancedrenalcellcarcinoma |